1:35 PM
Apr 18, 2017
 |  BC Extra  |  Clinical News

Circassia abandoning allergy field after Phase IIb miss

Circassia Pharmaceuticals plc (LSE:CIR) said it will no longer develop allergy therapeutics following the failure of dust mite program HDM-SPIRE in a Phase IIb trial. The company plans to focus on its respiratory business, including its new collaboration with AstraZeneca plc (LSE:AZN; NYSE:AZN) for chronic obstructive pulmonary disease drugs Tudorza Pressair aclidinium bromide and Duaklir Pressair aclidinium bromide/formoterol fumarate.

The trial’s primary endpoint evaluated patients’ combined scores for rhinoconjunctivitis symptoms...

Read the full 355 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >